Insomnia Therapeutics Global Market Report 2025

The insomnia therapeutics market size has grown strongly in recent years. It will grow from$3.03 billion in 2024 to $3.21 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth during the historic period can be attributed to the increasing prevalence of insomnia, greater awareness of sleep disorders, the rising adoption of cognitive behavioral therapy for insomnia (CBT-I), the expansion of pharmaceutical treatments, and the growing use of over-the-counter sleep aids.

The insomnia therapeutics market size is expected to see strong growth in the next few years. It will grow to$4.01 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth during the forecast period can be attributed to advancements in AI-driven sleep monitoring, increasing demand for personalized medicine, a growing geriatric population with sleep disorders, rising mental health awareness, and an expanding pipeline of novel insomnia drugs. Key trends in the forecast period include the integration of digital therapeutics in insomnia treatment, the rising preference for non-pharmacological therapies, the increasing adoption of wearable sleep trackers, the development of next-generation sleep medications, and the growth of telemedicine for sleep disorder management.

The rising stress levels and lifestyle changes are expected to drive the growth of the insomnia therapeutics market. These factors refer to the psychological and behavioral shifts in daily routines that contribute to emotional strain and disrupted sleep patterns. The constant digital connectivity in modern life erodes work-life boundaries, limiting time for proper mental rest and exacerbating stress levels. Insomnia therapeutics offer effective, science-backed treatment solutions that help restore healthy sleep patterns, alleviate sleep-related anxiety, and support mental well-being amid the pressures of modern life. For example, in May 2024, the American Psychiatric Association (APA) reported that the percentage of U.S. adults feeling more anxious rose from 32% in 2022 to 43% in 2024. As anxiety and stress levels climb, the demand for insomnia treatments is growing, further driving the market's expansion.

Leading companies in the insomnia therapeutics market are focusing on developing advanced therapies, such as dual orexin receptor antagonists (DORAs), to offer targeted treatment options with fewer side effects and improved safety profiles. DORAs are medications that block both orexin-1 and orexin-2 receptors in the brain, which are involved in promoting wakefulness. By inhibiting these receptors, DORAs help induce sleep and are particularly effective in treating chronic insomnia. In June 2023, Idorsia Pharmaceuticals Ltd. launched QUVIVIQ (daridorexant), a first-in-class DORA for the treatment of chronic insomnia disorder. This therapy reduces nighttime wakefulness without disrupting natural sleep architecture, offering patients improved sleep onset, maintenance, and daytime functioning. QUVIVIQ's approval marks a significant breakthrough in insomnia treatment, addressing the need for long-term, non-habit-forming therapeutic options.

In August 2022, ResMed Inc. acquired Mementor, a company providing digital health solutions for sleep disorders such as insomnia. This acquisition strengthens ResMed’s position in the insomnia therapeutics market by integrating Mementor’s evidence-based digital health app into its offerings. With the integration, ResMed aims to expand access to reimbursable, digital therapy solutions in Germany, advancing its digital sleep medicine strategy. Mementor's app offers a digital approach to insomnia treatment, providing users with personalized, therapeutic content that addresses the root causes of sleep disturbances. This acquisition enhances ResMed's ability to offer accessible and innovative insomnia treatment solutions.

Major players in the insomnia therapeutics market are Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Aurobindo Pharma, Astellas Pharma Inc., Acadia Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Idorsia Ltd, Minerva Neurosciences, Big Health, Neurovalens, Electromedical Products International Inc., Neurim Pharmaceuticals Ltd., Innovative Neurological Devices (IND), Blake Insomnia Therapeutics Inc., and Cerêve Inc.

North America was the largest region in the insomnia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in insomnia therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the insomnia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Insomnia therapeutics refer to treatments designed to manage and alleviate the symptoms of insomnia, a condition characterized by difficulty falling or staying asleep. These treatments include prescription medications, over-the-counter sleep aids, and non-pharmacological approaches such as cognitive behavioral therapy for insomnia (CBT-I).

The primary treatment types in insomnia therapeutics are drugs and medical devices. Drugs used in insomnia therapeutics are pharmacological agents specifically developed to treat sleep disorders by improving sleep initiation, maintenance, or overall sleep quality through mechanisms that regulate the sleep-wake cycle. These formulations include tablets, capsules, liquid solutions, and patches, and are administered through various routes such as oral, intravenous, transdermal, and others. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, clinics, and wellness centers.

The insomnia therapeutics market research report is one of a series of new reports that provides insomnia therapeutics market statistics, including insomnia therapeutics industry global market size, regional shares, competitors with an insomnia therapeutics market share, detailed insomnia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the insomnia therapeutics industry. This insomnia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The insomnia therapeutics market consists of sales of herbal sleep aids, wearable sleep devices, sleep-enhancing audio devices, aromatherapy products, smart mattresses, sleep masks with embedded technology, blue light-blocking glasses, and biofeedback devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.